Benitec Biopharma (NASDAQ:BNTC) Azioni

BENITEC BIOPHARMA INC

Benitec Biopharma

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Benitec Biopharma Inc

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $18 to $20.

News

Price Target

Analyst Ratings

BNTC

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $20

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy and maintains $28 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $28 Price Target

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday.
Shares of Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/25/03/44425486/micron-q2-earnings-revenue-beat-data-center-sales-triple-eps-beat-strong-guidance-shares-jump">second-quarter results</a>.
Micron reported second-quarter revenue of $8.05 billion, beating the consensus estimate of $7.89 billion. Total revenue was up from $5.82 billion on a year-over-year basis. The company reported second-quarter adjusted earnings of $1.56 per share, beating analyst estimates of $1.42 per share, according to Benzinga Pro.
Micron expects third-quarter revenue of $8.8 billion, plus or minus $200 million, versus estimates of $8.49 billion. The company anticipates third-quarter adjusted earnings of $1.57 per share, plus or minus 10 cents per share, versus estimates of $1.47 per share.
Micron shares fell 2.6% to $100.28 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares dipped 20% to $2.60 in pre-market trading.</li>
<li>MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>) fell 14.8% to $9.15 in pre-market trading.</li>
<li>Riverview Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) shares fell 11% to $4.80 in pre-market trading.</li>
<li>Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) fell 10.4% to $15.01 in today's pre-market trading. Benitec Biopharma recently reported interim clinical results for three subjects treated with BB-301 in Phase 1b/2a study.</li>
<li>Satellogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) fell 9.7% to $3.61 in pre-market trading.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) declined 8.5% to $3.88 in pre-market trading following weak fourth-quarter results.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) shares dipped 7.7% to $227.30 in pre-market trading. FedEx posted weaker-than-expected earnings for its third quarter, while sales topped estimates. The company also said it now sees fiscal 2025 revenue flat to slightly down year-over-year, compared to the prior forecast of approximately flat.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) fell 6% to $4.43 in pre-market trading following weak quarterly results.</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell 5.6% to $67.84 in pre-market trading. Nike reported better-than-expected third-quarter financial results. The athletic footwear and apparel company reported third-quarter revenue of $11.27 billion, beating analyst estimates of $11.01 billion.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

INNV

MTAL

RVSB

SATL

Micron Technology, Nike, FedEx And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 44.2% to $3.0 during Friday's pre-market session. The company's market cap stands at $34.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 29.87% to $1.0. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares rose 25.55% to $56.5. The company's market cap stands at $735.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 19.17% to $0.49. The company's market cap stands at $5.1 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock increased by 17.19% to $1.15. The company's market cap stands at $10.8 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares increased by 15.12% to $2.36. The company's market cap stands at $45.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) stock declined by 20.1% to $1.87 during Friday's pre-market session. The market value of their outstanding shares is at $73.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock declined by 19.7% to $2.61. The market value of their outstanding shares is at $352.9 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares fell 13.8% to $7.0. The market value of their outstanding shares is at $111.0 million. </li>
<li>Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) stock fell 13.37% to $3.5. The market value of their outstanding shares is at $85.0 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) stock fell 11.26% to $14.9. The market value of their outstanding shares is at $349.4 million. </li>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) shares fell 10.49% to $2.56. The company's market cap stands at $439.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTV

ELTX

GCTK

GELS

RNAZ

SVRA

TELA

12 Health Care Stocks Moving In Friday's Pre-Market Session

Shares of Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/OUST/earnings">better-than-expected fourth-quarter financial results.</a>
Ouster reported quarterly losses of 48 cents per share which beat the analyst consensus estimate of 59 cents per share. The company reported quarterly sales of $30.092 million which beat the analyst consensus estimate of $30.000 million.
Ouster shares jumped 7.5% to $9.01 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) gained 119.2% to $4.56 in pre-market trading after jumping 292% on Thursday.</li>
</ul>
<ul>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) rose 39.8% to $0.5780 in pre-market trading after gaining 6% on Thursday.</li>
<li>Patriot National Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNBK#NASDAQ">PNBK</a>) gained 36.8% to $1.45 in pre-market trading after the company announced over $50 million private placement.</li>
<li>Allurion Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NASDAQ">ALUR</a>) gained 32.3% to $3.02 in pre-market after the company announced results from its allurion program and low-dose GLP-1 therapy combination.</li>
<li>TEN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) gained 22.2% to $1.22 in pre-market trading after dipping 37% on Thursday. TEN Holdings recently announced a $1 million stock repurchase program.</li>
<li>Mill City Ventures III, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) gained 18.2% to $2.15 in pre-market trading.</li>
<li>DSS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSS#NYSE">DSS</a>) rose 13.6% to $1.05 in pre-market trading after gaining 4% on Thursday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) rose 11.7% to $13.40 in pre-market trading after dipping over 22% on Thursday.</li>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) gained 11.1% to $3.00 in pre-market trading after dipping 10% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) fell 67.2% to $0.0412 in pre-market trading after the company priced its upsized $16.5 million public offering of 126.9 million units at $0.13 per unit.</li>
<li>SAG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares fell 22.7% to $0.9048 in pre-market trading after jumping 73% on Thursday.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 20% to $2.60 in pre-market trading after declining 6% on Thursday.</li>
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) declined 17.4% to $1.14 in pre-market trading. Plus Therapeutics shares jumped 170% on Thursday after the company announced that the FDA accepted the name REYOBIQ for Co.&#8217;s lead asset.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) shares tumbled 14.5% to $0.8423 in pre-market trading after falling over 16% on Thursday.</li>
<li>Riverview Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) shares fell 11% to $4.80 in pre-market trading.</li>
<li>authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) dipped 10.4% to $5.63 in pre-market trading after gaining 15% on Thursday.</li>
<li>Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) fell 10.4% to $15.01 in today's pre-market trading. Benitec Biopharma recently reported interim clinical results for three subjects treated with BB-301 in Phase 1b/2a study.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) shares dipped 7.7% to $227.30 in pre-market trading. FedEx posted weaker-than-expected earnings for its third quarter, while sales topped estimates. The company also said it now sees fiscal 2025 revenue flat to slightly down year-over-year, compared to the prior forecast of approximately flat.</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) fell 5.6% to $67.84 in pre-market trading. Nike reported better-than-expected third-quarter financial results. The athletic footwear and apparel company reported third-quarter revenue of $11.27 billion, beating analyst estimates of $11.01 billion.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>

Photo: Courtesy: zignal_88 on Shutterstock.com

Intraday Update

ALUR

AUID

BHAT

MCVT

OUST

PNBK

PSTV

TNMG

USAR

XHLD

Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Benitec Biopharma Reports Interim Clinical Results For Three Subjects Treated With BB-301 In Phase 1b/2a Study

Citizens Capital Markets analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and maintains $18 price target.

Citizens Capital Markets Reiterates Market Outperform on Benitec Biopharma, Maintains $18 Price Target

WIIM

Benitec Biopharma shares are trading higher following a Q2 EPS beat.

Earnings

Earnings Beats

Benitec Biopharma Q2 2025 GAAP EPS $(0.33) Beats $(0.87) Estimate

Management

Benitec Biopharma's Megan Boston Confirmed As CFO

Baird analyst Brian Skorney initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $30.

Initiation

Baird Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $30

Guggenheim analyst Debjit Chattopadhyay reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy and maintains $17 price target.

Guggenheim Reiterates Buy on Benitec Biopharma, Maintains $17 Price Target

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent.

Benitec Biopharma Q1 2025 GAAP EPS $(0.48) Beats $(0.55) Estimate

Offerings

Benitec Biopharma Files For Mixed Shelf Of Up To $125M

Oppenheimer initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $35.

Oppenheimer Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $35

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) price target from $217 to $230. Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating. JPMorgan shares closed at $222.29 on Friday. <a href="https://www.benzinga.com/quote/jpm/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut the price target for Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) from $27 to $26. RBC Capital analyst Gregory Renza maintained an Outperform rating. Nurix Therapeutics shares closed at $23.63 on Friday. <a href="https://www.benzinga.com/quote/nrix/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised the price target for V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from $21 to $25. Stifel analyst Jim Duffy maintained a Buy rating. V.F. Corporation shares closed at $20.33 on Friday. <a href="https://www.benzinga.com/quote/vfc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) price target from $25 to $45. Wedbush analyst David Chiaverini upgraded the stock from Underperform to Neutral. Affirm shares closed at $47.08 on Friday. <a href="https://www.benzinga.com/quote/afrm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) price target from $13 to $11. Stifel analyst Mark Kelley maintained a Hold rating. Snap shares closed at $11.13 on Friday. <a href="https://www.benzinga.com/quote/snap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $68 to $71. Evercore ISI Group analyst John Pancari maintained an Outperform rating. Wells Fargo shares closed at $60.99 on Friday. <a href="https://www.benzinga.com/quote/wfc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) from $16 to $18. JMP Securities analyst Silvan Tuerkcan maintained a Market Outperform rating. Benitec Biopharma settled at $10.86 on Friday. <a href="https://www.benzinga.com/quote/bntc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) price target from $147 to $179. Piper Sandler analyst Peter Keith maintained an Overweight rating. Boot Barn shares closed at $159.36 on Friday. <a href="https://www.benzinga.com/quote/boot/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) from $67 to $80. Baird analyst David Manthey maintained a Neutral rating. Fastenal shares closed at $76.82 on Friday. <a href="https://www.benzinga.com/quote/fast/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen cut ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) price target from $131 to $114. TD Cowen analyst Jason Seidl downgraded the stock from Buy to Hold. ArcBest shares rose 1.4% to close at $105.95 on Friday. <a href="https://www.benzinga.com/quote/arcb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WFC stock? Here&#8217;s what analysts think:

AFRM

ARCB

BOOT

FAST

NRIX

SNAP

Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $16 to $18.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $18

<ul>
<li>-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-</li>
<li>-Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below-</li>
</ul>

Reported Saturday, Benitec Biopharma Reveals Data From Low-Dose BB-301 In Phase 1b/2a Study At World Muscle Society Congress

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock increased by 34.6% to $1.6 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares rose 17.68% to $3.26. The company's market cap stands at $104.9 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares rose 12.59% to $2.9. The market value of their outstanding shares is at $38.8 million. </li>
<li>Opthea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) shares moved upwards by 12.53% to $4.58. The company's market cap stands at $704.8 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) stock rose 11.53% to $10.25. The company's market cap stands at $108.1 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares rose 10.04% to $2.52. The market value of their outstanding shares is at $101.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares fell 57.4% to $0.25 during Tuesday's regular session. The company's market cap stands at $29.1 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock declined by 47.43% to $0.34. The market value of their outstanding shares is at $3.5 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock fell 40.26% to $2.08. The market value of their outstanding shares is at $99.5 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares decreased by 18.4% to $5.5. The market value of their outstanding shares is at $19.3 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 17.53% to $0.32. The market value of their outstanding shares is at $14.8 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock fell 17.46% to $0.49. The company's market cap stands at $12.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

APDN

BYSI

GRTS

MNPR

NUWE

SGMT

SNSE

STTK

XAIR

12 Health Care Stocks Moving In Tuesday's Intraday Session

Press Releases

Benitec Biopharma Announces Updated Investor Webcast Information

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Health Care

Benitec Biopharma to Participate in Upcoming Conferences in January and February

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

Benitec Biopharma to Participate in Upcoming Conferences in March

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

aTyr Pharma

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Celcuity

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Emergent BioSolutions

Heron Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Myriad Genetics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Verastem

XOMA Royalty

JMP Securities

HC Wainwright & Co.

Citizens Capital Markets

Baird

Guggenheim

Comments

Benitec Biopharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO